Recruiting
NCT07898371
Multiple Sclerosis
A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
+ 18 year(s)
Study targets participants aged 18 year(s) and older
All gender
This study targets all gender participants
N/A
not applicable
3000 participants
Study involves a large group of participants
1 locations
Available in numerous locations
Study Overview
This study aims to assess the real-world treatment patterns, data from patient reported outcomes, the effectiveness profile of tolebrutinib, and health care utilization data in routine practice. The decision to initiate tolebrutinib treatment is made by the treating neurologist as part of standard of care. Consideration and option of participation in the study will only be done once the treatment decision has been made, independent of study participation. Only upon signing the informed consent form (ICF) will the patient be enrolled in the study. The patient's participation in the study will not influence the MS treatment. Total study duration of study is 5 years per country comprising an approximately 24-months of enrollment period followed by a 36-month individual observational period.
Eligibility Criteria
Inclusion Criteria:
- Willing to participate with the ability to consent and sign an Informed Consent Form (ICF).
- Treatment decision according to approved local label. Retrospective inclusion of patients who had initiated tolebrutinib up to a maximum of 4 weeks prior to signing the ICF is allowed.
Exclusion Criteria:
- Participation in tolebrutinib long-term safety (LTS) study or any prior tolebrutinib study; experience with any other Bruton's Tyrosine Kinase (BTK) inhibitors.
- Current or planned/pending participation in a clinical study.
- Inability to comply with the study protocol
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.